hansen-chr-new-20.html
Novo Annual Report 2015
21 / 72
s ymphogen is a biopharmaceutical
company
that develops antibody mixture therapeutics for the treatment of cancer. o rexo is a specialty pharmaceutical
company
focused on the therapeutic areas of pain and inflammation.
symphogen
founded in 2000 headquartered in ballerup, denmark, with a clinical development unit in new jersey, usa major investors include
novo
a/s (from 2000), essex woodlands and pka private
company
board member representing
novo
a/s: aleks engel, asset director www.
symphogen
.com orexo founded in 1995 headquartered in uppsala, sweden major investors include
novo
a/s (from 2010) and healthcap revenue 2015: sek 228 million public
company
, listed on the stockholm stock exchange since 2005. code orx board member representing
novo
a/s: michael shalmi, head of large investments www.orexo.com news
symphogen
closed a eur 67.5 million financing subscribed by existing investors. fully enrolled 240 patients in a phase 2b study for sym004 in metastatic colorectal cancer. the product was fully transferred from merck serono earlier in the year. sym004 is a novel antibody mixture targeting metastatic colorectal cancer, gliablastoma, and quamous cell carcinoma of the head and neck. established a strategic collaboration with baxalta to develop six immuno-oncology antibodies. news orexo received fda approval for zubsolv ® for induction of buprenorphine maintenance therapy in patients with opioid dependence. announced the divestment of the subsidiary, kibion that markets the products heliprobe ® system, diabact ® ubt and iris? for the diagnosis of the gastric ulcer bacterium, helicobacter pylori using breath test technology. initiated the launch of a new higher zubsolv tablet strength (8.6 mg/2.1 mg buprenorphine/naloxone ciii sublingual tablets). entered into a settlement and license agreement with actavis laboratories fl, inc. to settle the patent litigation regarding abstral ® in the us. received sek 63.8 million milestone payment for abstral ® in europe. eivind kolding, ceo,
novo
was appointed chairman of the nomination committee. annual review 2015 21 large investments
envarsus-inogen-novo-22.html
